Clinical trial · Interventional
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
Phase III Trial of Neutron + Photon Radiation Versus Photon + Hypofractionated Intensity Modulated Radiation Therapy in Localized Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. It is not yet known which type of radiation therapy is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying different types of radiation therapy to compare how well they work in treating patients with stage I, stage II, or stage III prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Occurrence of chronic grade 2 or higher toxicity as measured by RTOG/EORTC late morbidity scoring scheme at 1, 4, 8, and 12 months after treatment, then every 6 months for 5 years, then annually
Secondary outcomes (1)
- measure
- Disease free survival at 1, 4, 8, and 12 months after treatment, then every 6 months for 5 years, then annually
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed adenocarcinoma of the prostate
* Stage I-III disease (T1-T3, N0, M0)
* No clinical or radiographic evidence of metastasis
* If prostate-specific antigen (PSA) ≥ 10.0 ng/mL and Gleason score is 7, a radioisotope bone scan must show no evidence of metastasis
* No evidence of lymphatic or visceral metastases of the abdomen or pelvis on CT scan or MRI
* PSA ≤ 20 ng/mL
* Gleason score ≤ 7 (if stage T3 , score must be \< 7)
PATIENT CHARACTERISTICS:
Performance status
* Not specified
Life expectancy
* More than 10 years
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer
PRIOR CONCURRENT THERAPY:
Endocrine therapy
* Prior hormonal therapy allowed provided it was initiated no more than 2 months ago, and may include the following:
* Luteinizing hormone-releasing hormone agonists (e.g., goserelin, leuprolide)
* Anti-androgens (e.g., flutamide, bicalutamide)
Radiotherapy
* No prior pelvic irradiation
Surgery
* No prior radical prostatectomyReferences
Publications (0)
Data not yet available